Expert view: The future of cell expansion for monoclonal antibody production
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
List view / Grid view
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
Endogenous human antibodies can be used to build and dismantle 2D and 3D DNA nanostructures, finds new research.
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
Immunogens can be used to coax the immune system into producing broadly neutralising antibodies to fight a HIV infection, making a vaccine against the condition more likely, say researchers.
Scientists have discovered that a plant-based compound called halofuginone activates a pathway that results in better antibodies and could improve the effectiveness of vaccines.
Therapeutic drugs based on biological materials (antibodies, hormones, cytokines, enzymes, fusion proteins) may have the ability to elicit an immune response in the host.
Researchers have developed a vaccine for HIV that has shown success in rabbits, by neutralising a wide range of HIV strains using bnAbs.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
A study has revealed a new antibody that reverses the effects of pulmonary arterial hypertension in rodents and cell models.
A new rabies vaccine strategy enhanced the speed and magnitude of the anti-rabies antibody responses and could improve the efficacy of currently used vaccines.
A new vaccine against the Staphylococcus aureus infection has proven effective in experiments with mice, with an 80 percent survival rate.
A study has demonstrated a novel vaccine design in mice which could be used to immunise patients against HIV.
Researchers have identified a set of three antibodies that they suggest could become the basis for a new antiviral treatment and inform the development of new influenza vaccines.
A new study has shown the specific cellular mechanisms that limit the ability of CD8 T cells to infiltrate the tumour microenvironment, which could guide new immunotherapeutic strategies in cancer.